Stoke Therapeutics, Inc. (STOK)
Nasdaq: STOK · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2014
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Mar 16, 2026 | Mar 18, 2025 | Mar 25, 2024 | Mar 6, 2023 | Mar 10, 2022 | Mar 9, 2021 | Mar 23, 2020 | · |
| Revenue | 184,420 | 36,555 | 8,780 | 12,405 | · | · | · | · |
| Research and development | 137,922 | 89,133 | 82,231 | 77,837 | 54,168 | 32,197 | 23,764 | 8,371 |
| Selling, general and administrative | 67,088 | 48,794 | · | · | · | · | · | · |
| General and administrative | · | 48,794 | 41,322 | 38,924 | 31,897 | 20,847 | 11,914 | 4,410 |
| Total operating expenses | 205,010 | 137,927 | 123,553 | 116,761 | 86,065 | 53,044 | 35,678 | 12,781 |
| Operating income | -20,590 | -101,372 | -114,773 | -104,356 | -86,065 | -53,044 | -35,678 | -12,781 |
| Interest expense | 9 | 26 | 49 | · | · | · | · | · |
| Interest and investment income | 13,765 | 12,664 | 9,957 | · | · | 744 | 3,351 | 270 |
| Interest income (expense), net | 13,756 | 12,638 | 9,908 | 3,122 | 120 | 700 | · | · |
| Other income (expense), net | -51 | -247 | 166 | 167 | 140 | 101r | 2 | -10 |
| Total non-operating income (expense) | 13,705 | 12,391 | 10,074 | 3,289 | 260 | 801 | 3,353 | 260 |
| Income tax expense | 0 | · | · | · | · | · | · | · |
| Net income including non-controlling interests | -6,885 | -88,981 | -104,699 | -101,067 | -85,805 | -52,243 | -32,325 | -12,521 |
| Net income | -6,885 | -88,981 | -104,699 | -101,067 | -85,805 | -52,243 | -32,325 | -12,521 |
| Earnings per share, basic | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | · | · | · |
| Earnings per share, diluted | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -2.34 | -1.56 | -1.80 | -17.65 |
| Weighted average shares, basic | 59,219,184 | 54,008,883 | 43,994,862 | 38,897,442 | 36,739,269 | · | · | · |
| Weighted average shares, diluted | 59,219,184 | 54,008,883 | 43,994,862 | 38,897,442 | 36,739,269 | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 36,739,269 | 33,488,456 | 17,971,443 | 709,336 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted